Bristol Myers Squibb and 2seventy bio’s Abecma gets positive FDA committee vote for multiple myeloma
In a significant development in the healthcare industry, Bristol Myers Squibb (NYSE: BMY) and 2seventy bio, Inc. (Nasdaq: TSVT) have announced a favorable vote by ... Read More
Novartis announces takeover bid for MorphoSys AG to boost oncology pipeline
In a significant move within the pharmaceutical industry, Novartis has entered into an agreement to launch a voluntary public takeover offer to acquire MorphoSys AG, ... Read More
AstraZeneca to acquire Gracell Biotechnologies for $1.2bn to expand cell therapy capabilities
AstraZeneca has announced a definitive agreement to acquire Gracell Biotechnologies Inc. (Gracell, NASDAQ: GRCL) for an upfront cash payment of $1.0 billion, representing a 62% ... Read More
Lilly announces promising results for Pirtobrutinib Phase 1/2 trials
Eli Lilly's oncology arm, Loxo@Lilly, disclosed that The New England Journal of Medicine (NEJM) has published an extensive analysis of results from the BRUIN Phase ... Read More
Takeda’s TAK-755 shows potential in Phase 3 trial for cTTP prophylaxis
Takeda Pharmaceutical Company has revealed promising interim results from its global Phase 3 trial of TAK-755, a recombinant ADAMTS13 protein in development for the prophylactic ... Read More
Legend Biotech announces submission of CARVYKTI application to EMA for multiple myeloma
Legend Biotech has announced the submission of a Type II variation application to the European Medicines Agency (EMA) for CARVYKTI (ciltacabtagene autoleucel or cilta-cel), based ... Read More
Bristol Myers Squibb gets Reblozyl EC approval for anemia associated with NTD beta thalassemia
Bristol Myers Squibb (BMY) has secured full marketing authorization for Reblozyl (luspatercept) from the European Commission (EC) for treating anemia associated with non-transfusion-dependent (NTD) beta ... Read More
BeiGene gets Brukinsa FDA approval for chronic lymphocytic leukemia
BeiGene has secured the approval of the US Food and Drug Administration (FDA) for the company’s Brukinsa (zanubrutinib) for the treatment of adult patients with ... Read More
FDA approves Janssen’s TECVAYLI for multiple myeloma treatment
The Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson, announced the US Food and Drug Administration's approval of its first bispecific T-cell engager antibody, ... Read More
Pfizer to acquire Oxbryta developer Global Blood Therapeutics for $5.4bn
Pfizer has agreed to acquire Global Blood Therapeutics (GBT), a publicly-listed American biopharma company, in a deal worth around $5.4 billion with an aim to ... Read More